Solicitations › Department of Health and Human Services › National Institutes of Health
Promega Assay Reagents to Support Complement-ARIE Mechanistic Toxicology Research
Closed — responses were due 21 Sep 2026 · No Set aside used · National Institutes of Health (NIH), HHS · Durham, NC · NAICS 325413 · Solicitation 75N98026Q01226
Following NAICS 325413? Get new solicitations in it by email as they post — no account needed.
Email me new ones
This solicitation has closed.
Responses were due 21 September 2026.
The record stays published because closed procurements are what a recompete is
built from — the follow-on is typically solicited 6–18 months before the
incumbent contract ends. Open solicitations like this one are linked below.
Solicitation details
Get new NAICS 325413 solicitations by email
This one has closed. We'll email you when new NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
1.0 DESCRIPTION This is a combined synopsis/solicitation for commercial products prepared in accordance with RFO FAR Part 12. This announcement constitutes the only solicitation. Offers are being requested, and a separate written solicitation will not be issued. Solicitation No. 75N98026Q01226 is issued as a Request for Quotation (RFQ) for Promega assay reagents to support Complement-ARIE mechanistic toxicology research. The Government intends to award a purchase order on a sole-source basis to Promega Corporation based on the Government's determination that Promega Corporation is the only source identified as capable of satisfying the Government's requirements. However, all responsible sources may submit a quotation that demonstrates their ability to satisfy the complete requirements identified in this RFQ and the attached requirements document. All timely quotations will be considered by the Government. This RFQ is being posted to the Governmentwide Point of Entry (GPE) in accordance with RFO FAR 5.201. This acquisition will be conducted in accordance with RFO FAR Part 12 Acquisition of Commercial Products and Commercial Services, using the simplified procedures at RFO FAR 12.201-1. The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to procure, on a sole source basis, Promega assay reagents from the manufacturer, Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin 53711. The Promega assay reagents are required to support Complement-ARIE research conducted by the National Center for Advancing Translational Sciences (NCATS) and NIEHS through the Mechanistic Toxicology Branch (MTB) within the Division of Translational Toxicology (DTT). The reagents will be used to assess cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems and will complement cell painting and omics endpoints. Continued use of the specified assay reagents is necessary to support the established experimental approach, maintain consistency and comparability of research results, and provide the required sensitivity for evaluating toxicity responses in small three-dimensional microtissue models. Due to the specialized nature of the Complement-ARIE research and the Government s requirement for the specific combination of assay reagents, luminescence/chemiluminescence-based detection, toxicological endpoints, and compatibility with the established experimental approach, the Government intends to procure these supplies on a sole-source basis from Promega Corporation. Promega Corporation manufactures the assay reagents identified in the Government s requirement and, based on the market research conducted, is the only source identified that can satisfy the Government s requirements. The Government has determined that these requirements are necessary to support the established research methodology, maintain comparability and reproducibility of results, and enable integration of the assay results with existing cell painting and omics-based analyses. The contractor shall provide the Promega assay reagents identified in the Government s requirement and associated quotation. The reagents shall support measurement of cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems. The contractor shall deliver the required supplies to NIEHS in Rall Building 101, laboratories E144-146, located at 111 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709. Acceptance will be demonstrated by successful delivery and the successful performance of the specified assays within the NIEHS laboratory. There is no travel for this purchase. Required delivery date: September 25, 2026 Delivery Location: NIEHS, Rall Building 101, Laboratories E144-146, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709 The applicable NAICS code is 325413 In-Vitro Diagnostic Substance Manufacturing. The applicable PSC is 6550 In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. Please see the attached requirements document titled 75N98026Q01226 Requirements Document for additional information. 2.0 UNIQUE QUALIFICATIONS OF THE CONTRACTOR The proposed contractor, Promega Corporation, is the manufacturer of the required assay reagents for the Complement-ARIE research conducted by NCATS and NIEHS. The required supplies involve specialized assay reagents designed to measure cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems. The requested reagents also provide luminescence/chemiluminescence-based detection and are intended to complement established cell-painting and omics-based endpoints. The Promega assay reagents are specialized research products that are required to support the Government s established experimental approach for evaluating toxicity-induced liver injury and associated cellular responses in human three-dimensional microphysiological systems. Due to the specific combination of required toxicological endpoints, detection technology, and compatibility with the established Complement-ARIE research methodology, use of an alternate source could require modifications to the experimental design and methodologies, affect assay sensitivity, and reduce the comparability and reproducibility of results across the research program. Accordingly, Promega Corporation is the only identified responsible source capable of providing the complete combination of assay reagents required to meet the Government s scientific and technical requirements while maintaining the established experimental approach. BASIS FOR AWARD The Government intends to issue a firm-fixed-price purchase order to Promega Corporation. However, all timely quotations received will be considered. To be considered for award, a quotation must demonstrate that the products offered satisfy all the Government's scientific and technical requirements identified in this RFQ and the attached requirements document. Award will be made to the responsible quoter whose quotation satisfies the Government's requirements and whose price is determined fair and reasonable. RESPONSE INSTRUCTIONS The response and any other information furnished must be in writing and must contain material in sufficient detail to allow the Office of Acquisition and Logistics Management (OALM) to determine whether the respondent can fulfill the requirement. Quotations shall identify the products being offered, manufacturer and part numbers, quantities, unit and total prices, delivery schedule, and sufficient technical information to demonstrate that the products offered satisfy all of the Government's scientific and technical requirements identified in the attached requirements document. All responses must be sent via email to Contract Specialist, Jordan Neal, at Jordan.Neal@nih.gov, copying Contracting Officer, Alice Pag n Pereira, at Alice.Pagan@nih.gov by no later than 12:00 pm Eastern Time on Monday, September 21, 2026. To be eligible for award, the contractor must be registered in System for Award Management (SAM.gov) in accordance with applicable requirements. Reference: 75N98026Q01226 on all correspondence.
Documents in the solicitation package
1 file is attached to this notice.
- 75N98026Q01226 - Requirements Document.pdf
Download all 1 file as one ZIP Free account, no credit card.
Reading them for requirements? FedSift turns the package into a compliance matrix — every requirement with the page it came from, exportable to Excel.
Or download them one at a time from SAM.gov.
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts
the compliance matrix, evaluation factors, key risks, win themes and
deal-breakers, each with a verbatim quote and the exact PDF page it came from. It
scores the opportunity against your company profile, tells you whether to bid as
prime or sub, and ranks teaming partners who could close your gaps.
Open the AI analysis in FedSift →
Free forever plan — no credit card.
Browse solicitations without an account; sign in for AI analysis and matching.
Market context: HHS and NAICS 325413
About the buyer and the industry, not this specific solicitation. Source: USASpending.gov award data, updated nightly.
- In fiscal year 2026, HHS obligated $11.9M across 96 contract actions under NAICS 325413.
- 70 contracts worth $47.0M in this category end within the next 18 months.
HHS contracts under NAICS 325413 →
Other open solicitations in NAICS 325413
All NAICS 325413 solicitations →
More from Department of Health and Human Services
All HHS solicitations →
Source: this notice on SAM.gov.
FedSift republishes public federal procurement data and is not affiliated with
the U.S. Government. Always confirm dates and requirements against SAM.gov
before responding.